Welcome and Introduction
Importance of Molecular Testing in NSCLC
Treatment Options for The Most Common Targetable Biomarkers for Advanced NSCLC: EGFR and KRAS
Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: ALK, ROS, RET, TRK, MET
Practical Considerations: Putting It All Together
Presentations will include clinical cases and panel discussions, with time for questions from the audience.
Date / Time
Sandip P. Patel, MD
Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California
Todd M. Bauer, MD
Senior Investigator, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Joshua Sabari, MD
Assistant Professor of Medicine
Division of Thoracic Medical Oncology
Department of Medical Oncology
NYU Langone Health Perlmutter Cancer Center
Attending Physician, Thoracic Medical Oncology
Department of Medicine
Perlmutter Cancer Center
NYU Langone Health
New York, New York
The goal of this program is to improve the knowledge and competence of learners to optimally assess biomarkers and then effectively and safely integrate novels agents into their practice for patients with NSCLC.
This program is intended for physicians and other healthcare professionals who care for patients with NSCLC.
Upon completion of this activity, participants should be able to:
- Assess new and emerging predictive biomarkers to guide treatment decisions for individual patients with all stages of NSCLC
- Plan therapeutic strategies for patients with NSCLC based on available evidence, tumor molecular profile, comorbidities, and expert recommendations
- Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, along with racial, age, and socioeconomic disparities
- Identify existing disparities in care and barriers to biomarker testing and clinical trial enrollment for all patients with NSCLC
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.